GlassScriptPhysician profile
William Taylor Bates
NPI 1720752199
$3,050.32
in general payments reported to CMS, 2019-2025
21 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $126 · 2023: $290 · 2024: $469 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $23.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.46 |
| Education | $23.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $499.68 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $414.56 | 2022-2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $414.13 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $340.07 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $300.78 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $249.59 | 2024-2025 | Spravato, Invega Sustenna |
| Harmony Biosciences LLC | $133.16 | 2025 | |
| Abbvie INC. | $103.95 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.69 | 2025 | Trintellix |
| Lundbeck LLC | $89.15 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $60.40 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.46 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $50.01 | 2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $47.69 | 2023-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $41.08 | 2025 | Uzedy, Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $40.11 | 2025 | Nuplazid |
| Collegium Pharmaceutical, INC. | $36.06 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $24.49 | 2025 | |
| Corium, LLC | $20.61 | 2025 | Azstarys |
| Hikma Pharmaceuticals USA | $18.08 | 2024 | Kloxxado |
| Tris Pharma INC | $14.57 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.